SCHEDULE 13G/A 0001234950 XXXXXXXX LIVE 5 Common Stock, par value $0.005 per share 03/31/2025 0000748592 Eterna Therapeutics Inc. 114082209 1035 Cambridge Street Suite 18A Cambridge MA 02141 Rule 13d-1(c) John D. Halpern b X1 0 5971830 0 5971830 5971830 N 9.6 IN Rows 6, 8, and 9 consist of (i) 5,856,830 shares of common stock, par value $0.005 per share (the "Common Stock"), of Ernexa Therapeutics Inc., a Delaware corporation (formerly Eterna Therapeutics Inc., the "Issuer") held by the John D. Halpern Revocable Trust (the "Trust"), a trust of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 115,000 shares of Common Stock of the Issuer (the "Warrant Shares") issuable upon exercise of that certain Pre-Funded Common Stock Purchase Warrant, in substantially the form as the form of Warrant filed as Exhibit 10.3 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 24, 2024 (the "Warrant"), issued by the Issuer in favor of the Trust which may be exercised at any time, at a nominal exercise price of $0.005 per Warrant Share. Row 11 is calculated based on 62,478,763 shares of Common Stock of the Issuer, which is derived from (i) 62,363,763 shares of the Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the SEC on May 7, 2025; plus (ii) 115,000 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. The number of shares beneficially owned in Rows 6, 8 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to the Trust pursuant to that certain Securities Purchase Agreement dated as of March 31, 2025 between the Issuer and the purchasers identified on the signature pages thereto, including the Trust (the "SPA"), following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025. Katherine H. Halpern b X1 0 5971830 0 5971830 5971830 N 9.6 IN As noted above, Rows 6, 8, and 9 consist of (i) 5,856,830 shares of the Common Stock of the Issuer held by the Trust, of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 115,000 Warrant Shares issuable upon exercise of the Warrant. Row 11 is calculated based on 62,478,763 shares of the Common Stock of the Issuer, which is derived from (1) 62,363,763 shares of Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the SEC on May 7, 2025; plus (ii) 115,000 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. The number of shares beneficially owned in Rows 6, 8 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to the Trust pursuant to the SPA, following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025. Eterna Therapeutics Inc. 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 John D. Halpern Katherine H. Halpern P.O. Box 540 Portsmouth, New Hampshire 03802 United States Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. John D. Halpern /s/ John D. Halpern 05/15/2025 Katherine H. Halpern /s/ Katherin H. Halpern 05/15/2025